Locations:
SearchAdvertisement
Real-world results reporting aims to make treatments safer and more effective
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Obstructing key protein allows for increased treatment uptake for taxane chemotherapy
Surgery, chemotherapy improve outcomes among EOCRC patients
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
An underdiagnosed condition in patients with cancer
Large cohort study finds no reduction in survival for patients managed with active surveillance compared to treated patients
Research enables precision medicine beyond patients with changed mutational status
Study finds drug safe and effective when combined with chemotherapy
Treatment may be a lifesaving option for patients with relapsed or refractory disease
Sarcopenia and sarcopenic obesity appear to increase risk of early chemotherapy termination
Advertisement
Advertisement